Evaluation of the Feasibility of Screening Tau Radiotracers Using an Amyloid Biomathematical Screening Methodology

The purpose of this study is to evaluate the feasibility of extending a previously developed amyloid biomathematical screening methodology to support the screening of tau radiotracers during compound development. 22 tau-related PET radiotracers were investigated. For each radiotracer, in silico MLogP, V x, and in vitro K D were input into the model to predict the in vivo K 1, k 2, and BPND under healthy control (HC), mild cognitive impaired (MCI), and Alzheimer's disease (AD) conditions. These kinetic parameters were used to simulate the time activity curves (TACs) in the target regions of HC, MCI, and AD and a reference region. Standardized uptake value ratios (SUVR) were determined from the integrated area under the TACs of the target region over the reference region within a default time window of 90–110 min. The predicted K 1, k 2, and BPND values were compared with the clinically observed values. The TACs and SUVR distributions were also simulated with population variations and noise. Finally, the clinical usefulness index (CUI) ranking was compared with clinical comparison results. The TACs and SUVR distributions differed for tau radiotracers with lower tau selectivity. The CUI values ranged from 0.0 to 16.2, with 6 out of 9 clinically applied tau radiotracers having CUI values higher than the recommend CUI value of 3.0. The differences between the clinically observed TACs and SUVR results showed that the evaluation of the clinical usefulness of tau radiotracer based on single target binding could not fully reflect in vivo tau binding. The screening methodology requires further study to improve the accuracy of screening tau radiotracers. However, the higher CUI rankings of clinically applied tau radiotracers with higher signal-to-noise ratio supported the use of the screening methodology in radiotracer development by allowing comparison of candidate radiotracers with clinically applied radiotracers based on SUVR, with respect to binding to a single target.

[1]  S. Gauthier,et al.  Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain , 2017, Alzheimer's Research & Therapy.

[2]  Mark E. Schmidt,et al.  Discovery of N-(Pyridin-4-yl)-1,5-naphthyridin-2-amines as Potential Tau Pathology PET Tracers for Alzheimer's Disease. , 2017, Journal of medicinal chemistry.

[3]  J. Trojanowski,et al.  Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.

[4]  Allen F. Brooks,et al.  High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection. , 2014, ACS chemical neuroscience.

[5]  R. Vandenberghe,et al.  Comparison of New Tau PET-Tracer Candidates With [18F]T808 and [18F]T807 , 2016, Molecular imaging.

[6]  C. Hock,et al.  ELISA-Quantitation of Phosphorylated Tau Protein in the Alzheimer’s Disease Brain , 1999, European Neurology.

[7]  Kazuhiko Yanai,et al.  Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. , 2014, Brain : a journal of neurology.

[8]  Kazuhiko Yanai,et al.  18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. , 2011, Brain : a journal of neurology.

[9]  Clifford R. Jack,et al.  An autoradiographic evaluation of AV-1451 Tau PET in dementia , 2016, Acta Neuropathologica Communications.

[10]  Jorge Sepulcre,et al.  Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.

[11]  Vincent Doré,et al.  In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  M. Lubberink,et al.  Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  Patrick R. Hof,et al.  Tau protein isoforms, phosphorylation and role in neurodegenerative disorders 1 1 These authors contributed equally to this work. , 2000, Brain Research Reviews.

[14]  Bradford C. Dickerson,et al.  Tau PET imaging in aging and early Alzheimer's disease , 2015 .

[15]  H. Kolb,et al.  [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease , 2013, Alzheimer's & Dementia.

[16]  Keith A. Johnson,et al.  Pharmacokinetic Evaluation of the Tau PET Radiotracer 18F-T807 (18F-AV-1451) in Human Subjects , 2017, The Journal of Nuclear Medicine.

[17]  H. Arai,et al.  [18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  D. Moechars,et al.  Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future. , 2015, Journal of medicinal chemistry.

[19]  H. Arai,et al.  18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease , 2016, The Journal of Nuclear Medicine.

[20]  Gunnar Antoni,et al.  Visualization of regional tau deposits using 3H-THK5117 in Alzheimer brain tissue , 2015, Acta neuropathologica communications.

[21]  Virginia M. Y. Lee,et al.  Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies , 2017, Brain : a journal of neurology.

[22]  A. Fagan,et al.  Multimodal techniques for diagnosis and prognosis of Alzheimer's disease , 2009, Nature.

[23]  Jans H. Alzate-Morales,et al.  Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[24]  Lin Xie,et al.  Radiosynthesis, Photoisomerization, Biodistribution, and Metabolite Analysis of 11C-PBB3 as a Clinically Useful PET Probe for Imaging of Tau Pathology , 2014, The Journal of Nuclear Medicine.

[25]  Hiroshi Watabe,et al.  Biomathematical screening of amyloid radiotracers with clinical usefulness index , 2017, Alzheimer's & dementia.

[26]  Graham Lappin,et al.  The phase 0 microdosing concept. , 2006, British journal of clinical pharmacology.

[27]  B. Ghetti,et al.  Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains , 2017, Alzheimer's Research & Therapy.

[28]  D. Fourney Commentary , 2011, Evidence-based spine-care journal.

[29]  K. Togashi,et al.  (18)F-labeled phenyldiazenyl benzothiazole for in vivo imaging of neurofibrillary tangles in Alzheimer's disease brains. , 2012, ACS medicinal chemistry letters.

[30]  Y. Tsuda,et al.  Stereoselectivity and enantiomer-enantiomer interactions in the binding of ibuprofen to human serum albumin. , 1997, Chirality.

[31]  T. Kudo,et al.  Quantitative analysis of neurofilament proteins in Alzheimer brain by enzyme linked immunosorbent assay system , 1999, Psychiatry and clinical neurosciences.

[32]  J. Hooker,et al.  A Philosophy for CNS Radiotracer Design , 2014, Accounts of chemical research.

[33]  W. Honer,et al.  Tau Proteins in the Temporal and Frontal Cortices in Patients With Vascular Dementia , 2015, Journal of neuropathology and experimental neurology.

[34]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[35]  W. Jagust,et al.  Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer’s Disease Patients Measured Using [18F] THK-5351 , 2016, PloS one.

[36]  R. Caselli,et al.  A Quantitative Analysis of Brain Soluble Tau and the Tau Secretion Factor , 2017, Journal of neuropathology and experimental neurology.

[37]  H. Watabe,et al.  Title: Prediction of the clinical standardized uptake value ratio in amyloid PET imaging using a biomathematical modeling approach towards the efficient development of a radioligand Short running title: Prediction of SUVR for amyloid PET probe Authors: , 2017 .

[38]  Min-Ying Su,et al.  Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. , 2014, Journal of Alzheimer's disease : JAD.

[39]  H. Watabe,et al.  Quantitative kinetic analysis of PET amyloid imaging agents [(11)C]BF227 and [(18)F]FACT in human brain. , 2015, Nuclear medicine and biology.

[40]  Ming-Rong Zhang,et al.  PET Quantification of Tau Pathology in Human Brain with 11C-PBB3 , 2015, The Journal of Nuclear Medicine.

[41]  Talakad G. Lohith,et al.  Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles , 2016, The Journal of Nuclear Medicine.

[42]  Denis Guilloteau,et al.  Brain [18F]FDDNP binding and glucose metabolism in advanced elderly healthy subjects and Alzheimer's disease patients. , 2013, Journal of Alzheimer's disease : JAD.

[43]  N. Okamura,et al.  Preclinical Evaluation of [18F]THK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer , 2016, Molecular Imaging and Biology.

[44]  Kazuhiko Yanai,et al.  18 F-THK 523 : a novel in vivo tau imaging ligand for Alzheimer ’ s disease , 2011 .

[45]  Kazuhiko Yanai,et al.  Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer’s disease pathology , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[46]  Gunnar Antoni,et al.  Tracer Kinetic Analysis of (S)-18F-THK5117 as a PET Tracer for Assessing Tau Pathology , 2016, The Journal of Nuclear Medicine.

[47]  Christopher C Rowe,et al.  Tau imaging: early progress and future directions , 2015, The Lancet Neurology.

[48]  In vivo quantification of neurofibrillary tangles with [18F]MK-6240 , 2018, Alzheimer's Research & Therapy.

[49]  H. Arai,et al.  Novel 18F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease , 2013, The Journal of Nuclear Medicine.

[50]  Michael Brady,et al.  A Biomathematical Modeling Approach to Central Nervous System Radioligand Discovery and Development , 2009, Journal of Nuclear Medicine.